| Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial AX Zhu, RS Finn, J Edeline, S Cattan, S Ogasawara, D Palmer, ... The Lancet Oncology 19 (7), 940-952, 2018 | 2108 | 2018 |
| Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, phase III trial RS Finn, BY Ryoo, P Merle, M Kudo, M Bouattour, HY Lim, V Breder, ... Journal of Clinical Oncology 38 (3), 193-202, 2020 | 1439 | 2020 |
| Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up A Vogel, A Cervantes, I Chau, B Daniele, JM Llovet, T Meyer, JC Nault, ... Annals of oncology 29, iv238-iv255, 2018 | 866 | 2018 |
| CheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular … T Yau, JW Park, RS Finn, AL Cheng, P Mathurin, J Edeline, M Kudo, ... Annals of Oncology 30, v874-v875, 2019 | 737 | 2019 |
| Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial T Yau, JW Park, RS Finn, AL Cheng, P Mathurin, J Edeline, M Kudo, ... The Lancet Oncology 23 (1), 77-90, 2022 | 657 | 2022 |
| Gemcitabine and oxaliplatin chemotherapy or surveillance in resected biliary tract cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): a randomized phase III study J Edeline, M Benabdelghani, A Bertaut, J Watelet, P Hammel, JP Joly, ... Journal of Clinical Oncology 37 (8), 658-667, 2019 | 434 | 2019 |
| Adjuvant therapy for resected biliary tract cancer: ASCO clinical practice guideline RT Shroff, EB Kennedy, M Bachini, T Bekaii-Saab, C Crane, J Edeline, ... Journal of Clinical Oncology 37 (12), 1015-1027, 2019 | 383 | 2019 |
| Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised … E Garin, L Tselikas, B Guiu, J Chalaye, J Edeline, T de Baere, E Assenat, ... The lancet Gastroenterology & hepatology 6 (1), 17-29, 2021 | 363 | 2021 |
| Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma J Edeline, E Boucher, Y Rolland, E Vauléon, M Pracht, C Perrin, ... Cancer 118 (1), 147-156, 2012 | 356 | 2012 |
| Dosimetry based on 99mTc-macroaggregated albumin SPECT/CT accurately predicts tumor response and survival in hepatocellular carcinoma patients treated with 90Y-loaded glass … E Garin, L Lenoir, Y Rolland, J Edeline, H Mesbah, S Laffont, P Porée, ... Journal of Nuclear Medicine 53 (2), 255-263, 2012 | 277 | 2012 |
| KEYNOTE-224: Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib. AX Zhu, RS Finn, S Cattan, J Edeline, S Ogasawara, DH Palmer, ... Journal of Clinical Oncology 36 (4_suppl), 209-209, 2018 | 275 | 2018 |
| Male breast cancer. Evolution of treatment and prognostic factors. Analysis of 489 cases B Cutuli, CCS Le-Nir, D Serin, Y Kirova, Z Gaci, C Lemanski, ... Critical reviews in oncology/hematology 73 (3), 246-254, 2010 | 253 | 2010 |
| Radioembolization plus chemotherapy for first-line treatment of locally advanced intrahepatic cholangiocarcinoma: a phase 2 clinical trial J Edeline, Y Touchefeu, B Guiu, O Farge, D Tougeron, I Baumgaertner, ... JAMA oncology 6 (1), 51-59, 2020 | 224 | 2020 |
| LBA34 Primary results from the phase III LEAP-002 study: Lenvatinib plus pembrolizumab versus lenvatinib as first-line (1L) therapy for advanced hepatocellular carcinoma (aHCC) RS Finn, M Kudo, P Merle, T Meyer, S Qin, M Ikeda, R Xu, J Edeline, ... Annals of Oncology 33, S1401, 2022 | 216 | 2022 |
| Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a … RK Kelley, M Ueno, C Yoo, RS Finn, J Furuse, Z Ren, T Yau, HJ Klümpen, ... The Lancet 401 (10391), 1853-1865, 2023 | 213 | 2023 |
| Results of KEYNOTE-240: phase 3 study of pembrolizumab (Pembro) vs best supportive care (BSC) for second line therapy in advanced hepatocellular carcinoma (HCC). RS Finn, BY Ryoo, P Merle, M Kudo, M Bouattour, HY Lim, VV Breder, ... Journal of Clinical Oncology 37 (15_suppl), 4004-4004, 2019 | 211 | 2019 |
| Boosted selective internal radiation therapy with 90Y-loaded glass microspheres (B-SIRT) for hepatocellular carcinoma patients: a new personalized promising … E Garin, L Lenoir, J Edeline, S Laffont, H Mesbah, P Porée, L Sulpice, ... European journal of nuclear medicine and molecular imaging 40, 1057-1068, 2013 | 200 | 2013 |
| High prognostic value of 18F-FDG PET for metastatic gastroenteropancreatic neuroendocrine tumors: a long-term evaluation H Bahri, L Laurence, J Edeline, H Leghzali, A Devillers, JL Raoul, ... Journal of Nuclear Medicine 55 (11), 1786-1790, 2014 | 195 | 2014 |
| KEYNOTE-240 investigators. Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, phase III trial RS Finn, BY Ryoo, P Merle, M Kudo, M Bouattour, HY Lim, V Breder, ... J Clin Oncol 38 (3), 193-202, 2020 | 187 | 2020 |
| Biliary tract cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up☆ A Vogel, J Bridgewater, J Edeline, RK Kelley, HJ Klümpen, D Malka, ... Annals of Oncology 34 (2), 127-140, 2023 | 174 | 2023 |
jean-luc RaoulAdresse e-mail validée de ico.unicancer.fr
